SANCTURA XR Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Sanctura Xr, and when can generic versions of Sanctura Xr launch?

Sanctura Xr is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sanctura Xr

A generic version of SANCTURA XR was approved as trospium chloride by GLENMARK PHARMS LTD on August 13^th, 2010.

Subscribe

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SANCTURA XR?
What are the global sales for SANCTURA XR?
What is Average Wholesale Price for SANCTURA XR?

Summary for SANCTURA XR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	8
Patent Applications:	879
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SANCTURA XR
DailyMed Link:	SANCTURA XR at DailyMed

Drug patent expirations by year for SANCTURA XR

Recent Clinical Trials for SANCTURA XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Neil M. Resnick	Phase 4
National Institute on Aging (NIA)	Phase 4
Karuna Pharmaceuticals	Phase 1

See all SANCTURA XR clinical trials

Paragraph IV (Patent) Challenges for SANCTURA XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SANCTURA XR	Extended-release Capsules	trospium chloride	60 mg	022103	1	2009-03-02

US Patents and Regulatory Information for SANCTURA XR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SANCTURA XR

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007	7,759,359	⤷ Subscribe
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007	7,781,449	⤷ Subscribe
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007	7,781,448	⤷ Subscribe
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007	7,763,635	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SANCTURA XR

See the table below for patents covering SANCTURA XR around the world.

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
European Patent Office	1680110	FORME DOSIFIEE QUOTIDIENNE DE TROSPIUM (ONCE DAILY DOSAGE FORMS OF TROSPIUM)	⤷ Subscribe
Hong Kong	1088547	ONCE DAILY DOSAGE FORMS OF TROSPIUM TROSPIUM	⤷ Subscribe
Spain	2359375		⤷ Subscribe
Canada	2537103	FORME DOSIFIEE QUOTIDIENNE DE TROSPIUM (ONCE DAILY DOSAGE FORMS OF TROSPIUM)	⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for SANCTURA XR

Recent Clinical Trials for SANCTURA XR

Paragraph IV (Patent) Challenges for SANCTURA XR

Make Better Decisions: Try a trial or see plans & pricing